SCHEMBL10148737

SCHEMBL10148737

CC(=O)OCC1OC=C[C@@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.47
CYP2D6 P10635 3/20 0.47
THRB P10828 2/20 0.47
MAPT P10636 6/20 0.46
CYP3A4 P08684 3/20 0.46
ALDH1A1 P00352 3/20 0.46
TSHR P16473 2/20 0.46
CYP2C19 P33261 2/20 0.46
CA12 O43570 7/20 0.45
CA1 P00915 7/20 0.45
CA2 P00918 7/20 0.45
CA9 Q16790 7/20 0.45
MAPK1 P28482 1/20 0.43
NR3C1 P04150 1/20 0.43
FYN P06241 1/20 0.43
ADRA2A P08913 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
ADRA2B P18089 1/20 0.43
DRD4 P21917 1/20 0.43
DRD3 P35462 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13427968 1.00 HSD17B10 (0.47) HSD17B10CYP2D6THRBMAPTCYP3A4
SCHEMBL13402445 1.00 HSD17B10 (0.47) HSD17B10CYP2D6THRBMAPTCYP3A4
SCHEMBL25985483 1.00 HSD17B10 (0.47) HSD17B10CYP2D6THRBMAPTCYP3A4
SCHEMBL12083311 1.00 HSD17B10 (0.47) HSD17B10CYP2D6THRBMAPTCYP3A4
SCHEMBL15494654 1.00 HSD17B10 (0.47) HSD17B10CYP2D6THRBMAPTCYP3A4
SCHEMBL78636 1.00 HSD17B10 (0.47) HSD17B10CYP2D6THRBMAPTCYP3A4
SCHEMBL12968777 1.00 HSD17B10 (0.47) HSD17B10CYP2D6THRBMAPTCYP3A4
SCHEMBL62522 1.00 HSD17B10 (0.47) HSD17B10CYP2D6THRBMAPTCYP3A4
SCHEMBL8602259 1.00 HSD17B10 (0.47) HSD17B10CYP2D6THRBMAPTCYP3A4
SCHEMBL7150795 0.92 HSD17B10 (0.46) HSD17B10CYP2D6THRBMAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4108262-A1 CROSS-LINKED NUCLEOSIDE AND NUCLEOTIDE USING SAME OSAKA UNIVERSITY (JP) 2022-12-28 EP disclosed
US-9447133-B2 Synthetic oligosaccharides for moraxella vaccine Visterra, Inc. (US) 2016-09-20 US disclosed
US-20140148592-A1 Synthetic Oligosaccharides for Moraxella Vaccine Visterra, Inc. 2014-05-29 US disclosed
US-20130102759-A1 Synthetic Oligosaccharides for Moraxella Vaccine SYNGLYCO, INC. 2013-04-25 US disclosed
US-8114970-B2 Synthetic heparin monosaccharides ALCHEMIA LIMITED (AU) 2012-02-14 US disclosed
US-20100323976-A1 NOVEL ANTI-INFLAMMATORY PRO-DRUGS ACADEMISCH MEDISCH CENTRUM (NL) 2010-12-23 US disclosed
US-20100222546-A1 METHODS FOR THE PREPARATION OF FUNCTIONALIZED PEPTIDES, PROTEINS AND CARBOHYDRATES AND THEIR CONJUGATES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-09-02 US disclosed
US-20090187013-A1 SYNTHETIC HEPARIN PENTASACCHARIDES ALCHEMIA LIMITED (AU) 2009-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090187013-A1 SYNTHETIC HEPARIN PENTASACCHARIDES HPSE, DDOST, STT3A HSD17B10 1735/4885CYP2D6 3080/4885THRB 2070/4885
US-20130102759-A1 Synthetic Oligosaccharides for Moraxella Vaccine FUT6, OSTC, MGAM HSD17B10 1808/4885CYP2D6 1577/4885THRB 3464/4885
US-20140148592-A1 Synthetic Oligosaccharides for Moraxella Vaccine FUT6, FUT5, MGAM HSD17B10 1839/4885CYP2D6 1845/4885THRB 3695/4885
US-20100222546-A1 METHODS FOR THE PREPARATION OF FUNCTIONALIZED PEPTIDES, PROTEINS AND CARBOHYDRATES AND THEIR CONJUGATES PTMS, STT3A, GCG HSD17B10 2692/4885CYP2D6 3438/4885THRB 3315/4885
US-20100323976-A1 NOVEL ANTI-INFLAMMATORY PRO-DRUGS MSR1, ARG1, CD209 HSD17B10 1992/4885CYP2D6 705/4885THRB 1944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.